Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11524980 | 0.96 | TSHR (0.50) | TSHRTHRBLMNAANPEPSLC22A1 | |
| SCHEMBL88650 | 0.96 | TSHR (0.50) | TSHRTHRBLMNAANPEPSLC22A1 | |
| SCHEMBL488468 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL487870 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL2078883 | 0.93 | TSHR (0.47) | TSHRTHRBLMNAANPEPSLC22A1 | |
| SCHEMBL556924 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL11331724 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL8845927 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL332105 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL29385729 | 0.93 | TSHR (0.57) | TSHRTHRBLMNASLC22A1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344599-A | Nano sheet manganese-based metal organic framework material, preparation method thereof and photoelectric device | 邯郸学院 | 2024-07-16 | — | — | CN | claimed |
| CN-117954722-A | Method for synchronously realizing repair and surface coating of waste lithium ion battery positive electrode material regeneration | 中南大学 | 2024-04-30 | — | — | CN | claimed |
| CN-116917341-A | Sugar chain and method for producing pharmaceutical product containing sugar chain | 第一三共株式会社 | 2023-10-20 | — | — | CN | claimed |
| EP-1810967-B1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INT INC (TW) | 2014-07-30 | — | — | EP | claimed |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2008-02-14 | — | — | US | claimed |
| EP-1810967-A1 | Processes and intermediates for the preparations of prostaglandins | Chirogate International Inc. (TW) | 2007-07-25 | — | — | EP | claimed |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2007-07-19 | — | — | US | claimed |
| WO-1995027715-A2 | METHOD OF MANUFACTURE OF (-)GALANTHAMINE IN HIGH YIELD AND PURITY SUBSTANTIALLY FREE OF EPIGALANTHAMINE | CIBA-GEIGY CORPORATION (US) | 1995-10-19 | — | — | WO | claimed |
| US-5428159-A | Resolution of racemic mixture; reduction | CIBA-GEIGY CORPORATION (US) | 1995-06-27 | — | — | US | claimed |
| US-12497375-B2 | Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom | CHIROGATE INTERNATIONAL INC. (TW) | 2025-12-16 | — | — | US | disclosed |
| US-12497374-B2 | Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom | CHIROGATE INTERNATIONAL INC. (TW) | 2025-12-16 | — | — | US | disclosed |
| US-20250304519-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | CHIROGATE INTERNATIONAL INC. (TW) | 2025-10-02 | — | — | US | disclosed |
| US-12428361-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | CHIROGATE INTERNATIONAL INC. (TW) | 2025-09-30 | — | — | US | disclosed |
| EP-4273131-B1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | CHIROGATE INT INC (TW) | 2025-07-02 | — | — | EP | disclosed |
| EP-1549350-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | Fresenius Kabi Deutschland GmbH (DE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004032971-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | disclosed |
| US-5856590-A | HYDROGENATING 4-T-BUTYLCYCLOHEXANONE BY USING A SPECIFIC RUTHENIUM-PHOSPHINE COMPLEX AS A CATALYST IN THE PRESENCE OF A BASE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0240175-B1 | INOSOSE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-4824943-A | Inosose derivatives and production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0240175-A1 | Inosose derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428361-B2 | Processes and intermediates for the preparation of carbaprostacyclin analogues | PTGIS, PTGIR, PTGES | TSHR 4673/4885THRB 4728/4885LMNA 500/4885 |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | TSHR 2650/4885THRB 3669/4885LMNA 1678/4885 |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | TSHR 2650/4885THRB 3669/4885LMNA 1678/4885 |
| US-12497374-B2 | Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom | PTGIS, PTGER1, PTGIR | TSHR 2552/4885THRB 3405/4885LMNA 346/4885 |
| US-20250304519-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | PTGIS, PTGIR, PTGES | TSHR 4673/4885THRB 4728/4885LMNA 500/4885 |
| US-12497375-B2 | Processes and intermediates for the preparations of benzoprostacyclin analogues and benzoprostacyclin analogues prepared therefrom | PTGIS, PTGIR, PTGES | TSHR 3431/4885THRB 4431/4885LMNA 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.